Ghana approves Oxford’s malaria vaccine for children aged 5 to 36 monthsBMJ 2023 ; 381 doi: https://doi.org/10.1136/bmj.p850 (Published 14 April 2023) Cite this as: BMJ 2023;381:p850
- Elisabeth Mahase
- The BMJ
Ghana’s Food and Drugs Authority (FDA) has approved a malaria vaccine developed by the University of Oxford for use in children aged 5 months to 3 years.
Manufactured by the Serum Institute of India, the R21/Matrix-M malaria vaccine contains the circumsporozoite protein, secreted by the malaria parasite, fused to hepatitis B surface antigen, and delivered alongside Novavax’s Matrix-M adjuvant, which stimulates the entry of antigen presenting cells …